Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01861717 · ClinicalTrials.gov registry record · Phase 4
A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.
A Phase 4 study, sponsored by Saint John's Cancer Institute.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT01861717 is a Phase 4 study that was terminated before completion, run by Saint John's Cancer Institute. The registered enrollment target is 4 participants.
The verdict
NCT01861717, a Phase 4 study, was terminated before completion, sponsored by Saint John's Cancer Institute.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
If someone is diagnosed with a pituitary tumor that causes acromegaly (too much growth hormone) the treatment is to have it surgically removed. This study has two phases. The first phase provides medical treatment with a drug that will be provided for 3 months before surgery to see if complications of surgery are reduced and to see whether or not remission improves following surgery if you have this medical treatment. The drug administered is approved by the FDA for long-term treatment of acromegaly. It is not routinely administered before surgery, and is therefore experimental as used in this way. All other procedures performed during this research are standard of care with the exception of the 3 questionnaires to be completed at each visit. The second phase of this study is from 3 months until 12 months after surgery and is only for people who do not go into remission after the operation. This phase assesses the possible remission of acromegaly after resuming the drug treatment for an additional 3 to 9 months. The drug will be prescribed by your physician as part of your regular medical care and will not be included as part of the study. All other procedures performed during this research are standard of care with the exception of the 3 questionnaires to be completed at each visit. The study lasts approximately 16 months - 3 month before surgery and 12 months after surgery.
Interventions
- DRUG lanreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2013-05 |
| Est. Completion | 2016-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01861717
The ClinicalTrials.gov registry entry for NCT01861717 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Saint John's Cancer Institute, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lanreotide is the first listed.
NCT01861717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01861717 about?
NCT01861717 is a clinical study titled "A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.". If someone is diagnosed with a pituitary tumor that causes acromegaly (too much growth hormone) the treatment is to have it surgically removed. This study has two phases. The first phase provides medical treatment with a drug that will be provided for 3 months before surgery to see if complications...
What is the current status of trial NCT01861717?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2013-05. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01861717?
The interventions under investigation include: lanreotide (DRUG).
Who is sponsoring clinical trial NCT01861717?
This trial is sponsored by Saint John's Cancer Institute, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.